Insider Sale: 10% owner at $HQL Sells 36,536 Shares
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 14 2025
0mins
Source: NASDAQ.COM
Insider Trading Activity: Capital Management, L.P. Saba sold 36,536 shares of $HQL on February 12, 2025, representing about 1.1% of their holdings, and now owns 3,276,181 shares. In the past six months, insiders have made 9 trades, with 8 being sales.
Institutional Investor Movements: In the most recent quarter, 24 institutional investors increased their positions in $HQL stock while 38 decreased theirs, indicating mixed sentiment among large shareholders.
Analyst Views on HQL
About HQL
abrdn Life Sciences Investors (the Fund), formerly Tekla Life Sciences Investors, is a non-diversified closed-end management investment company. The Fund's investment objective is long-term capital appreciation through investment in United States and foreign companies in the life sciences industry, including biotechnology, pharmaceutical, diagnostics, managed healthcare and medical equipment, hospitals, healthcare information technology and services, devices and supplies, and agriculture and environmental management. The Fund invests primarily in securities of public and private companies, which have the potential for above-average growth. The Fund invests up to 20% of its net assets in securities of foreign issuers, expected to be located primarily in Western Europe, Canada and Japan, and securities of United States issuers that are traded primarily in foreign markets. The Fund's investment adviser is abrdn Inc.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
